Chemoprevention in Barrett's Esophagus

Current Status

Muhammad H. Zeb, Anushka Baruah, Sarah K. Kossak, Navtej Singh Buttar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chemoprevention in Barrett's esophagus is currently applied only in research settings. Identifying pathways that can be targeted by safe, pharmaceutical or natural compounds is key to expanding the scope of chemoprevention. Defining meaningful surrogate markers of cancer progression is critical to test the efficacy of chemopreventive approaches. Combinatorial chemoprevention that targets multiple components of the same pathway or parallel pathways could reduce the risk and improve the efficacy of chemoprevention. Here we discuss the role of chemoprevention as an independent or an adjuvant management option in BE-associated esophageal adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)391-413
Number of pages23
JournalGastroenterology Clinics of North America
Volume44
Issue number2
DOIs
StatePublished - Jun 1 2015

Fingerprint

Barrett Esophagus
Chemoprevention
Adenocarcinoma
Biomarkers
Research
Pharmaceutical Preparations
Neoplasms

Keywords

  • Barrett's esophagus
  • Chemoprevention
  • Chronic reflux
  • Esophageal adenocarcinoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Chemoprevention in Barrett's Esophagus : Current Status. / Zeb, Muhammad H.; Baruah, Anushka; Kossak, Sarah K.; Buttar, Navtej Singh.

In: Gastroenterology Clinics of North America, Vol. 44, No. 2, 01.06.2015, p. 391-413.

Research output: Contribution to journalArticle

Zeb, Muhammad H. ; Baruah, Anushka ; Kossak, Sarah K. ; Buttar, Navtej Singh. / Chemoprevention in Barrett's Esophagus : Current Status. In: Gastroenterology Clinics of North America. 2015 ; Vol. 44, No. 2. pp. 391-413.
@article{e26b63104eb64473a59919261d3b2488,
title = "Chemoprevention in Barrett's Esophagus: Current Status",
abstract = "Chemoprevention in Barrett's esophagus is currently applied only in research settings. Identifying pathways that can be targeted by safe, pharmaceutical or natural compounds is key to expanding the scope of chemoprevention. Defining meaningful surrogate markers of cancer progression is critical to test the efficacy of chemopreventive approaches. Combinatorial chemoprevention that targets multiple components of the same pathway or parallel pathways could reduce the risk and improve the efficacy of chemoprevention. Here we discuss the role of chemoprevention as an independent or an adjuvant management option in BE-associated esophageal adenocarcinoma.",
keywords = "Barrett's esophagus, Chemoprevention, Chronic reflux, Esophageal adenocarcinoma",
author = "Zeb, {Muhammad H.} and Anushka Baruah and Kossak, {Sarah K.} and Buttar, {Navtej Singh}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.gtc.2015.02.009",
language = "English (US)",
volume = "44",
pages = "391--413",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Chemoprevention in Barrett's Esophagus

T2 - Current Status

AU - Zeb, Muhammad H.

AU - Baruah, Anushka

AU - Kossak, Sarah K.

AU - Buttar, Navtej Singh

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Chemoprevention in Barrett's esophagus is currently applied only in research settings. Identifying pathways that can be targeted by safe, pharmaceutical or natural compounds is key to expanding the scope of chemoprevention. Defining meaningful surrogate markers of cancer progression is critical to test the efficacy of chemopreventive approaches. Combinatorial chemoprevention that targets multiple components of the same pathway or parallel pathways could reduce the risk and improve the efficacy of chemoprevention. Here we discuss the role of chemoprevention as an independent or an adjuvant management option in BE-associated esophageal adenocarcinoma.

AB - Chemoprevention in Barrett's esophagus is currently applied only in research settings. Identifying pathways that can be targeted by safe, pharmaceutical or natural compounds is key to expanding the scope of chemoprevention. Defining meaningful surrogate markers of cancer progression is critical to test the efficacy of chemopreventive approaches. Combinatorial chemoprevention that targets multiple components of the same pathway or parallel pathways could reduce the risk and improve the efficacy of chemoprevention. Here we discuss the role of chemoprevention as an independent or an adjuvant management option in BE-associated esophageal adenocarcinoma.

KW - Barrett's esophagus

KW - Chemoprevention

KW - Chronic reflux

KW - Esophageal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84929879338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929879338&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2015.02.009

DO - 10.1016/j.gtc.2015.02.009

M3 - Article

VL - 44

SP - 391

EP - 413

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 2

ER -